- Yahoo財經
美股日誌｜納指首破萬七點 英偉達爆上7%
美股在假期後先升後回，受惠英偉達上達1,100美元帶動，納斯達克指數曾歷史性突破17,000點以上，午市一度近抹去所有升幅，惟最終能守穩在心理關口收市；道瓊斯指數曾跌近300點，標普500指數則近平收。債市向下，美國國債拍賣需求弱，10年期國債息率升7點子以上。中東局勢升溫，紐約期油升2.7%。
- Benzinga
Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Breast Cancer Study (UPDATED)
Editor’s Note: The title of the story is updated to correct the reference to ‘Breast’ cancer instead of ‘Lung’ cancer. Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from hase 3 KEYNOTE-522 trial of Keytruda in high-risk early-stage triple-negative breast cancer (TNBC). The study evaluated Keytruda in combination with chemotherapy as a pre-operative (neoadjuvant) treatment and then continuing as a single agent after surgery (adjuvant). The study met its overall survival (OS) endpoint.
- Insider Monkey
Is Merck & Co., Inc. (NYSE:MRK) the Best Dow Stock To Buy According to Hedge Funds?
We recently identified the best dow stocks according to hedge funds. Even though Merck & Co., Inc. (NYSE:MRK) ranks on our list, it’s not the best pick among hedge funds. Moreover, the company is one of the top two Dow stocks in the healthcare sector but it is not the best. You can check the […]
